Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information ...
Source: marketscreener.com
Hoffman La Roche News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hoffman La Roche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hoffman La Roche Today - Breaking & Trending Today
EU and UK Consider First Stand-Alone Disparagement Cases | Skadden, Arps, Slate, Meagher & Flom LLP
The development of case law on disparagement has, to date, been driven mainly by the French competition authority, or has been addressed under consumer protection or other national...
Source: jdsupra.com
Biologics and Biosimilars Landscape: IP, Policy, and Market Developments | Fish & Richardson
In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price...
Source: jdsupra.com
Here's how the EU and industry will spend €120M on health research this spring | Science
Science|Business plans to roll out a newsletter tailored for research and innovation professionals. This article provides a sneak peek into the kind of information you may expect in the coming weeks, ahead of a full launch this spring. The European Health Initiative (IHI) has a new set of calls for interdisciplinary projects open this spring, looking to inject €120 million, to be matched by industry, in health research and innovation.
Source: sciencebusiness.net
LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC
The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.
Source: onclive.com